2009年に、クロストリジウム・ディフィシル感染症 (CDI) の治療について経口バンコマイシンとフィダキソマイシンを比較した北米での第III相臨床試験についてよい結果が報告された[15][16]。試験は臨床的治癒のプライマリーエンドポイント(主要評価項目)を満たし、フィダキソマイシンが経口バンコマイシンに対して非劣性であることを示した (92.1% vs. 89.8%)。加えて、試験は再発のセカンダリーエンドポイント(副次的評価項目)を満たした: フィダキソマイシンを投与された被験者の再発率が13.3%であったのに対して、経口バンコマイシン投与群では24.0%であった。さらに、試験は完全治癒の探索的エンドポイントを満たした(フィダキソマイシン群77.7% vs. バンコマイシン群67.1%)[17]。
^Revill, P.; Serradell, N.; Bolós, J. (2006). “Tiacumicin B”. Drugs of the Future31 (6): 494. doi:10.1358/dof.2006.031.06.1000709.
^“Fidaxomicin”. Drugs in R&D10: 37. (2012). doi:10.2165/11537730-000000000-00000.
^Theriault, Robert J.; Karwowski, James P.; Jackson, Marianna; Girolami, Roland L.; Sunga, Gabriela N.; Vojtko, Charlene M.; Coen, Lyle J. (1987). “Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity.”. J. Antibiot.40 (5): 567–574. doi:10.7164/antibiotics.40.567.
^Hochlowski, J. E.; Swanson, S. J.; Ranfranz, L. M.; Whittern, D. N.; Buko, A. M.; Mcalpine, J. B. (1987). “Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination.”. J. Antibiot.40 (5): 575–588. doi:10.7164/antibiotics.40.575.
^Parenti, F.; Pagani, H.; Beretta, G. (1975). “Lipiarmycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies”. J. Antibiot.28 (4): 247–252. doi:10.7164/antibiotics.28.247. ISSN 0021-8820.
^Sergio, Somma; Pirali, G.; White, R.; Parenti, F. (1975). “Lipiarmycin, a new antibiotic from Actinoplanes. III. Mechanism of action”. J. Antibiot.28 (7): 543–549. doi:10.7164/antibiotics.28.543. ISSN 0021-8820.
^Omura, Satoshi; Imamura, Nobutaka; Oiwa, Ruiko; Kuga, Hiroshi; Iwata, Rimiko; Masuma, Rokuro; Iwai, Yuzuru (1986). “Clostomicins, new antibiotics produced by Micromonospora echinospora subsp. armeniaca subsp. nov. I Production, isolation, and physico-chemical and biological properties”. J. Antibiot.39 (10): 1407–1412. doi:10.7164/antibiotics.39.1407. ISSN 0021-8820.
^Takahashi, Yoko; Iwai, Yuzuru; Omura, Satoshi (1986). “Clostomicins, new antibiotics produced by Micromonospora echinospora subsp. armeniaca subsp. nov. II Taxonomic study of the producing microorganism”. J. Antibiot.39 (10): 1413–1418. doi:10.7164/antibiotics.39.1413. ISSN 0021-8820.
^Louie, T. J.; Emery, J.; Krulicki, W.; Byrne, B.; Mah, M. (2008). “OPT-80 Eliminates Clostridium difficile and is Sparing of Bacteroides Species during Treatment of C. Difficile Infection”. Antimicrobial Agents and Chemotherapy53 (1): 261–3. doi:10.1128/AAC.01443-07. PMC: 2612159. PMID 18955523. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2612159/.
^Johnson, Stuart (2009). “Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes”. Journal of Infection58 (6): 403–10. doi:10.1016/j.jinf.2009.03.010. PMID 19394704.
^Srivastava, Aashish; Talaue, Meliza; Liu, Shuang; Degen, David; Ebright, Richard Y; Sineva, Elena; Chakraborty, Anirban; Druzhinin, Sergey Y et al. (2011). “New target for inhibition of bacterial RNA polymerase: 'switch region'”. Current Opinion in Microbiology14 (5): 532–43. doi:10.1016/j.mib.2011.07.030. PMC: 3196380. PMID 21862392. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3196380/.
^“Optimer's North American phase 3 Fidaxomicin study results presented at the 49th ICAAC” (プレスリリース), Optimer Pharmaceuticals, (2009年9月16日), http://www.news-medical.net/news/20090916/Optimers-North-American-phase-3-Fidaxomicin-study-results-presented-at-the-49th-ICAAC.aspx2013年5月7日閲覧。
^“Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment” (プレスリリース), Optimer Pharmaceuticals, (2009年5月17日), http://www.reuters.com/article/2009/05/17/idUS33839+17-May-2009+PRN200905172013年5月7日閲覧。
^“Low recurrence rate among patients with C. difficile infection treated with fidaxomicin”. 49th interscience conference on antimicrobial agents and chemotherapy. San Francisco. (September 12–15, 2009)
^Louie, Thomas J.; Miller, Mark A.; Mullane, Kathleen M.; Weiss, Karl; Lentnek, Arnold; Golan, Yoav; Gorbach, Sherwood; Sears, Pamela et al. (2011). “Fidaxomicin versus vancomycin for Clostridium difficile infection”. New England Journal of Medicine364 (5): 422–31. doi:10.1056/NEJMoa0910812. PMID 21288078.
^Peterson, Molly (2011年4月5日). “Optimer wins FDA panel's backing for antibiotic fidaxomicin”. Bloomberg. http://www.bloomberg.com/news/2011-04-05/optimer-wins-fda-advisory-panel-s-backing-for-fidaxomicin-1-.html
^Nordqvist, Christian (2011年5月27日). “Dificid (fidaxomicin) approved for Clostridium difficile-associated diarrhea”. Medical News Today. http://www.medicalnewstoday.com/articles/226796.php